Background {#Sec1}
==========

Cancer-related fatigue (CRF) is one of the most common and complex symptoms experienced by patients diagnosed with cancer. The National Comprehensive Cancer Network (NCCN) defines CRF as "a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning" \[[@CR1]\]. Fatigue associated with cancer has a complex aetiology. It results from the interaction of two factors: those related to the disease itself or its treatment, and reduced physical activity \[[@CR2], [@CR3]\]. For this reason, the treatment of CRF should be multi-faceted and include, among others, physiotherapy \[[@CR1]\]. The maintenance of physical activity plays an important role in the treatment of fatigue. The application of selected physiotherapy methods enables patients to increase their physical activity, reduce fatigue and improve their functional status, which has a direct positive impact on their quality of life \[[@CR4]--[@CR27]\]. The issues of evaluating the effectiveness of physiotherapy programmes in the treatment of CRF have been the subject of interest for numerous researchers. Most studies were conducted in patient populations undergoing an intensive anticancer regime (i.e. chemotherapy or radiation therapy) or those successfully treated \[[@CR4]--[@CR22]\]. Much less interest was devoted to the merits of inclusion of physiotherapy in the treatment of CRF in patients with advanced cancer who are not given causal treatment anymore and receive palliative care \[[@CR23]--[@CR27]\]. The following study constitutes an attempt to assess the advisability of including physiotherapy as a treatment for CRF in patients with advanced cancer who were receiving palliative care. The aims of the study were to assess the effect of authorial physiotherapy programme on the intensity of CRF and comorbid symptoms and to evaluate whether the patients were satisfied with such kind of treatment.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

The study was designed as a randomized, controlled trial. The study protocol was approved by the Bioethics Committee of the L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun (KB 156/2009). Participants were recruited from the Palliative Care Department, Bydgoszcz University Hospital No. 1 and from the in-patient and home care provided by the Blessed Father Popieluszko Hospice in Bydgoszcz between January 2010 and May 2011. Eligible patients admitted to the palliative care service were identified by their physicians and informed about the study. After giving their preliminary consent to participating in the study, patients were offered detailed information and had the opportunity to ask questions. Patients had 2 days to decide whether to participate, which was confirmed by their submission of written consent. The inclusion criteria were diagnosis of advanced cancer, intensity of fatigue ≥4 in a 10-point NRS (Numerical Rating Scale) obtained during the first visit, survival expectancy of a month at the very least, functional status allowing the patient to participate in the proposed therapy, ≥18 years old and written consent to participate in the study. The exclusion criteria were anaemia (haemoglobin ≤8 g/dl), the existence of comorbidities causing fatigue (e.g. multiple sclerosis, Parkinson's disease, heart failure), infection requiring antibiotics, age \<18 and inability to understand written and spoken Polish.

Randomization {#Sec4}
-------------

Patients were randomized into the therapy group and the control group at the ratio of 1:1. Patients were assigned to respective groups using a list of numbers ranked in no particular order, with each new patient assigned a subsequent available number from the list. Even numbers designated the therapy group, while odd ones the control group.

Sample size calculation {#Sec5}
-----------------------

At the planning stage of the research protocol, the number of patients required to meet the objectives of the study was specified. The following assumptions were adopted for the calculation of the number of sub-groups: normal distribution of obtained values in the sample, target test power \>90% and the value of statistical significance for the difference---alpha \<0.05 (type I error), beta (type II error) \<10%, combined standard deviation (sigma) of 10% of the average and a two-way test of the null hypothesis assuming no differences in mean values of the studied parametres between the two groups. Moreover, the following effectiveness criteria of the therapeutic methods (differences in mean values of the evaluated parametres) were applied:Comparison of two dependent means---effective final treatment effect was defined as a 25% reduction in fatigue after 2 weeks of physiotherapy \[[@CR28]--[@CR30]\]Comparison of two independent means (therapeutic and control groups)---the final difference in fatigue severity between the therapy group and the control group was set at 25%

The required numbers were similar and totalled respectively 21 and 23. Due to the specifics of the population studied---the severity of the disease and the high risk of discontinuation of the study due to deterioration in the general condition of the patient or death, the target number of patients in each group (therapy and control) was set at 30.

Main outcome measures {#Sec6}
---------------------

The primary outcomes were use to measure the severity of fatigue and its impact on daily functioning and well-being (Brief Fatigue Inventory---BFI) and intensity of other symptoms associated with the disease (Edmonton Symptom Assessment Scale---ESAS).

The BFI has nine items, with the items measured on 0--10 numeric rating scales. Three items ask patients to rate the severity of their fatigue at its "worst", "usual" and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine". Six items assess the extent to which fatigue interfered with different aspects of the patient's life during the past 24 h. The interference items include general activity, mood, walking ability, normal work (includes both work outside the home and housework), relations with other people and enjoyment of life. The interference items are measured on a 0--10 scale, with 0 being "does not interfere" and 10 being "completely interferes" \[[@CR31]\]. The selection of this particular tool was dictated by its concise and simple form as well as the capacity to assess both the fatigue severity and its impact on patient's daily activities.

ESAS assists in the assessment of nine symptoms common in patients diagnosed with cancer: pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, well-being and breathlessness. The severity at the time of assessment of each symptom is rated from 0 to 10 on a numerical scale, 0 meaning that the symptom is absent and 10 that it is of the worst possible severity \[[@CR32]\].

Additionally, patient satisfaction was also evaluated in the treatment group (satisfaction scores, SS). To that end, points of satisfaction were used ranging from −3 to +3 (where −3 means complete dissatisfaction, 0 no change and +3 complete satisfaction).

Additionally, data were collected on the following variables:Demographic details such as gender, age and primary diagnosisKarnofsky Performance Scale Index

Interventions {#Sec7}
-------------

Patients in the therapy group were included into the physiotherapy program. During the 2-week study period, there were six therapy sessions in total (three per week). Each individual session lasted 30 min. The physiotherapy programme included active exercises of the upper and lower limbs, selected techniques of myofascial release (MFR) and selected techniques of proprioceptive neuromuscular facilitation (PNF). Physiotherapy sessions were always conducted by the same therapist, licensed in PNF method and trained in the application of myofascial release techniques.

For the study design, see Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study design

Parallel treatment {#Sec8}
------------------

In line with the research protocol, no restrictions were imposed on parallel pharmacological treatment. Patients received their previous medications, which were entered in the clinical outcomes record. In the event that during the study a patient was started on a new regimen that might affect fatigue severity, it was decided that the patient should be excluded from the statistical analysis evaluating the effect of physiotherapy on CRF.

Additionally, throughout the study, the intensity of symptoms was monitored using ESAS.

The study protocol assumed that any increase in the severity of symptoms such as pain, nausea, depression, anxiety and breathlessness by at least two points on a 0--10 scale (observed during two consecutive visits) excluded a patient from the statistical analysis that assessed the effect of physiotherapy on CRF. Such an assumption was based on observations from the study by Yennu et al. and Yennurajalingam et al. \[[@CR33], [@CR34]\] in an advanced cancer population, which showed that the intensity of these symptoms strongly correlated with fatigue severity.

Statistical analysis {#Sec9}
--------------------

The statistical analysis of the study results was performed using Statistica 9.1 for Windows.

The obtained data are presented as mean or median values ± SD (standard deviation) or 95% CI (confidence interval). The distribution of variables was verified using the Shapiro-Wilk test. Comparisons of statistical significance of differences between the median values of parametres on successive observation days and between groups were performed using one- and two-way ANOVA (analysis of variance) with an appropriate number of repeats. In order to assess the significance of differences in the tested parametres at individual measurement points, a post hoc LSD (least significant difference) test was used. The significance of differences between mean values in the treatment and control groups was assessed using Student's *t* test for independent samples (normal variable distribution) or the Mann-Whitney *U* test. The power of the statistical analysis was 90%; the differences between groups or the analysed time points were considered statistically significant at *P* \< 0.05.

Results {#Sec10}
=======

Characteristics of study participants {#Sec11}
-------------------------------------

The study included 60 patients (*n* = 60). Participants were randomized into the therapy group and the control group at the ratio of 1:1. Study groups (therapy and control) did not differ significantly with respect to age, tumour location and the study site. However, a significant gender difference was observed with respect to the assignment to the control or therapy groups, respectively (*P* = 0.03). Demographic and clinical characteristics of the patients qualified for the study are shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical characteristics of patients qualified for the studyDataTherapy groupControl group*P*Age (mean ± SD)72.4 ± 9.569.3 ± 13.70.32GenderF = 15 (50%)F = 24 (80%)0.03M = 15 (50%)M = 6 (20%)Tumour locationAlimentary system, *n* = 7Alimentary system, *n* = 80.33Urogenital system, *n* = 8Urogenital system, *n* = 5Lung, *n* = 2Lung, *n* = 3CNS, *n* = 4CNS, *n* = 1Mammary gland, *n* = 2Mammary gland, *n* = 6Haematological, *n* = 2Haematological, *n* = 4Indefinite origin, *n* = 4Indefinite origin, *n* = 2Mouth, *n* = 1Skin, *n* = 1Study siteHome care, *n* = 24Home care, *n* = 210.54Hospice, *n* = 3Hospice, *n* = 6PCD, *n* = 3PCD, *n* = 3KPSI46.0 ± 7.248.0 ± 11.00.41Fatigue\
NRS, 0--106.8 ± 1.16.5 ± 1.40.41*P* borderline level of statistical significance, *SD* standard deviation, *M* male, *F* female, *CNS* central nervous system, *PCD* palliative care department, *KPSI* Karnofsky Performance Scale Index, *NRS* numeric rating scale

Parallel treatment {#Sec12}
------------------

In the course of the study, drug regimen was modified in two patients (one in each group) whose general condition had deteriorated, which excluded them from the study. These patients were also excluded from the statistical analysis of the impact of physiotherapy on the fatigue level. None out of the 60 patients in the study sample was on the anticancer therapy.

Discontinuation of the study {#Sec13}
----------------------------

The study was discontinued for two patients (*n* = 1, therapy group and *n* = 1, control group). The cause of their death was advanced cancer. Those patients were excluded from the statistical analysis of the impact of physiotherapy on the severity of fatigue. They were the same patients who needed modified pharmacological treatment.

Effect of physiotherapy program on fatigue (BFI) {#Sec14}
------------------------------------------------

The analysis of the impact of physiotherapy program on the severity of fatigue included 29 patients from the treatment group and 29 patients from the control group. It was found that physiotherapy program significantly reduced fatigue severity in patients evaluated using the BFI. After 12 days, the results demonstrated a significant decrease in fatigue scores (BFI) compared with baseline (Wilcoxon test):In the treatment group on all the questions, mean score 6.4 ± 1.0 vs. 4.4 ± 1.4, *P* \< 0.01In the control group on questions 1 and 3, mean score 6.13 ± 1.4 vs. 5.9 ± 1.44, *P* \< 0.01

As compared with the control group, the treated individuals had significantly lower scores on the BFI on questions 1, 2, 3, 4a, 4b, 4e and 4f. Significant differences were observed on average as of day 8 of physiotherapy (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 2Mean change in BFI score from baseline (questions 1--3). Legend: rate your (1) level of fatigue right now, (2) level of fatigue during the past 24 h, and (3) the worst level of fatigue during the past 24 h Fig. 3Mean change in BFI score from baseline (questions 4a--4f). Legend: rate how fatigue has interfered with the following: 4a---general activity, 4b---mood, 4c---walking ability, 4d---normal work, 4e---relations with other people and 4f---enjoyment of life).

Impact of physiotherapy program on the severity of fatigue and other symptoms (ESAS) {#Sec15}
------------------------------------------------------------------------------------

Throughout the study, the severity of symptoms was evaluated using ESAS both in the treatment and in the control groups. At baseline, no significant differences were observed regarding ESAS parametre values between the groups (Table [2](#Tab2){ref-type="table"}). However, the comparison of scores for individual symptoms between baseline and the evaluation at the end of the study revealed a statistically significant beneficial effect of therapy in terms of reduced severity of the following: pain, fatigue, depression, anxiety, drowsiness, well-being and improved appetite (*P* \< 0.01) (Table [3](#Tab3){ref-type="table"}). Similar effects were not observed in the control group (Table [4](#Tab4){ref-type="table"}). After 14 days of physiotherapy, the therapy group compared with the control group reported a statistically significant reduced severity of fatigue and drowsiness; moreover, patients in the therapy group rated their well-being higher (Table [2](#Tab2){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}).Table 2Scores representing the severity of symptoms evaluated using ESAS in both subsets at baseline and after 12 days of physiotherapySymptoms (ESAS)Treatment group (*n* = 29)Control group (*n* = 29)*P*pain_11.5 ± 1.91.7 ± 2.10.6fatigue_16.8 ± 1.16.5 ± 1.40.4nausea_10.4 ± 1.01.1 ± 2.20.1depression_12.9 ± 2.32.9 ± 2.50.9anxiety_12.7 ± 2.32.7 ± 2.51.0drowsiness_13.6 ± 2.94.0 ± 2.70.6appetite_14.3 ± 2.94.0 ± 3.00.7well-being_14.8 ± 0.95.3 ± 1.30.1breathlessness_11.0 ± 1.80.9 ± 1.60.9pain_121.2 ± 1.51.7 ± 2.00.2fatigue_124.6 ± 1.66.3 ± 1.2\<0.01nausea_120.3 ± 0.80.9 ± 2.00.1depression_122.7 ± 2.12.8 ± 2.60.8anxiety_122.5 ± 2.12.5 ± 2.50.9drowsiness_122.3 ± 2.13.8 ± 2.7\<0.05appetite_123.1 ± 2.53.8 ± 2.80.4well-being_123.0 ± 1.25.0 ± 1.3\<0.01breathlessness_120.8 ± 1.50.9 ± 1.60.7*ESAS* Edmonton Symptom Assessment Scale, *P* borderline level of significance Table 3Scores representing the severity of symptoms evaluated using ESAS in the treatment group at baseline and after 12 days of physiotherapySymptoms (ESAS)symptom_1symptom_12*P*Pain1.5 ± 1.91.2 ± 1.5\<0.01Fatigue6.8 ± 1.14.6 ± 1.6\<0.01Nausea0.4 ± 1.00.3 ± 0.80.08Depression2.9 ± 2.32.7 ± 2.1\<0.01Anxiety2.7 ± 2.32.5 ± 2.1\<0.01Drowsiness3.6 ± 2.92.3 ± 2.1\<0.01Appetite4.3 ± 2.93.1 ± 2.5\<0.01Well-being4.8 ± 0.93.0 ± 1.2\<0.01Breathlessness1.0 ± 1.80.8 ± 1.50.18*symptom_1* intensity of a particular symptom on day 1 of observation, *symptom_12* intensity of a particular symptom on day 12 of observation, *ESAS* Edmonton Symptom Assessment Scale, *P* borderline level of significance Table 4Scores representing the severity of symptoms evaluated using ESAS in the control group at baseline and after 12 days of physiotherapySymptoms (ESAS)symptom_1symptom_12*P*Pain1.7 ± 2.11.7 ± 2.00.16Fatigue6.5 ± 1.46.3 ± 1.20.031Nausea1.1 ± 2.20.9 ± 2.00.33Depression2.9 ± 2.52.8 ± 2.60.33Anxiety2.7 ± 2.52.5 ± 2.50.16Drowsiness4.0 ± 2.73.8 ± 2.70.08Appetite4.0 ± 3.03.8 ± 2.80.057Well-being5.3 ± 1.35.0 ± 1.30.022Breathlessness0.9 ± 1.60.9 ± 1.61.0*symptom_1* intensity of a particular symptom on day 1 of observation, *symptom_12* intensity of a particular symptom on day 12 of observation, *ESAS* Edmonton Symptom Assessment Scale, *P* borderline level of significance Fig. 4Self-rated severity of symptoms on consecutive observation days (ESAS)

Satisfaction with physiotherapy program {#Sec16}
---------------------------------------

At the end of physiotherapy program, the mean level of patient satisfaction was 1.6 ± 0.8 (min. = 0, max. = 3). Of the 29 patients under observation, 26 rated the therapy as positive (+3, *n* = 3; +2, *n* = 14; +1, *n* = 9), whereas three patients rated it as neither positive nor negative.

Discussion {#Sec17}
==========

One of the elements of multifaceted symptom management in palliative care is physiotherapy. The main aim of physiotherapy in this patient population is to improve quality of life by way of alleviating troublesome symptoms and allowing the patients to function at an optimal level \[[@CR35]\]. The effectiveness of physiotherapy in the treatment of selected symptoms in patients with advanced cancer has been confirmed on numerous occasions. These symptoms include, among others, myofascial pain, lymphoedema, breathlessness, constipation or motor deficits secondary to neurological disorders \[[@CR36]--[@CR41]\].

CRF is rarely recognized as an indication for physiotherapy. The effect of physiotherapy programs on CRF in patients with advanced cancer had not been extensively studied. So far, the issue of physical exercises used for relieving fatigue in patients with advanced cancer was analysed only by Porock et al., Buss et al., Oldervoll et al., Van den Dungen et al. and Cheville et al. \[[@CR24]--[@CR28]\]. In their study, Porock et al. \[[@CR24]\] included only 11 patients with advanced cancer, suffering from fatigue. The study lasted 28 days and patients did not follow a single exercise therapy. The therapy involved exercises in bed, exercises in a sitting position, treadmill walking, cycle-ergometer exercises and dancing to the rhythm of favourite music. The exercise programs were tailored to the needs and physical capacity of individual patients. Therefore, individual interventions differed significantly in duration (ranging from 22 to 180 min per week). Although the authors did not observe any significant reduction in fatigue levels within the studied group, they pointed to the fact that the therapy regimens patients received did not increase their fatigue levels. Furthermore, the applied therapy regimens were positively evaluated by the patients, as they tangibly increased patients' daily physical activity. Buss et al. also attempted to assess the effectiveness of exercise interventions in reducing fatigue in the terminal hospice cancer patients \[[@CR25]\]. They assessed the effect of a single, well-defined, reproducible across the entire group of patients' exercise program on quality of life and fatigue in the hospice terminal cancer patients. The study group comprised 38 patients. Their analysis showed that, on average, after 3 weeks of a physical therapy exercise program, a significant decrease in fatigue levels was observed, while in the control group, it increased after 2 weeks of observation. It should be noted, however, that patients with short life expectancy (approx. 1--2 months) were among those admitted into the study by Buss et al. A similar criterion was used in the present study, i.e. approx. 1--3 months. For that reason, a timeline for the study was set at 2 weeks. Extending time frames of interventions in the case of short life expectancy patients increases a risk of their non-completion of a study. This is usually associated with deterioration of general condition, disease progression or death. Oldevoll et al. \[[@CR26]\] pursued their study for 8 weeks. Patients with advanced cancer with a life expectancy \<2 years were included in the study. Out of 231 patients, 68 (29%) were lost as a result of disease progression. The study evaluated the effects of a group exercise intervention, supervised by a physiotherapist. The exercise group had two exercise sessions per week over an 8-week period. Each session lasted 50--60 min and included a warm-up (10--15 min), circuit training with six stations (30 min) and stretching/relaxation (10--15 min). The analysis showed no significant reduction in fatigue levels in the study group. The applied intervention enhanced physical performance. The gait and muscle strength test results were significantly improved after 8 weeks of physical exercise. Improvement in physical fitness was also noted by van den Dungen et al. \[[@CR27]\]. Their non-randomized pilot study comprised 26 palliative care patients with advanced cancer. Participants followed an individually graded group exercise program, consisting of resistance training and aerobic exercise, twice a week during 6 weeks. Apart from improved physical fitness, the authors observed improved quality of life and reduced fatigue in patients. Cheville et al. \[[@CR28]\] assessed the effectiveness of a home-based physiotherapy. Sixty-six adults with stage IV lung or colorectal cancer were admitted into the study. They were randomized, in an 8-week trial, to usual care or incremental walking and home-based strength training. The exercising participants were instructed during a single physiotherapy visit and subsequently exercised 4 days or more per week; training and step-count goals were advanced during bimonthly telephone calls. A home-based exercise program seems capable of improving the mobility, fatigue and sleep quality of patients with stage IV lung and colorectal cancer.

Much more research on the evaluation of physiotherapy treatment in terms of CRF reduction was conducted in populations of patients undergoing an intensive oncological regimen and those who have been successfully treated. Results of research in this area show that the treatment groups achieve a statistically more effective fatigue reduction compared with controls. The authors have identified exercise as a beneficial and valuable form of treatment for fatigue among patients undergoing intensive anticancer therapy and patients with chronic fatigue that persists despite completed oncological treatment. At the same time, they signalled the need for research aimed at optimizing the type, intensity and duration of specific therapeutic interventions. The need to develop clear guidelines on the use of physiotherapy in the treatment of fatigue was also confirmed by a survey conducted among British physiotherapists working with cancer patients and members of the Association of Chartered Physiotherapists in Oncology and Palliative Care (ACPOPC) \[[@CR42]\].

Studies evaluating the effectiveness of selected physiotherapy methods in the treatment of fatigue support the use of this form of therapy among patients diagnosed with cancer. However, there are substantial differences among individual researchers concerning the duration of the therapy and its frequency. The authors of the publications studied, among others, the effectiveness of an exercise regimen carried out individually or in groups 2--7 times a week for 2--8 weeks. The duration of a single therapy session ranged from 20 to 90 min. The protocol adopted for the present study included 30-min physiotherapy sessions three times a week for 2 weeks. The planned follow-up period proved to be long enough to observe changes in fatigue severity due to physiotherapy, since statistically significant differences were already observed on average as of day 8 of the intervention. Simultaneously, in the vast majority of patients (*n* = 58), there was no disease progression or increased severity of symptoms; hence, they did not require additional pharmacological treatment. The comparison of ESAS scores between baseline and the day the observation ended showed statistically significant beneficial effects of the physiotherapy. It may have had a significant impact on the high level of treatment satisfaction.

The proposed physiotherapy program, including active exercises of upper and lower extremities, selected techniques of myofascial relaxation and PNF, was devised by the author of the study. The selection of individual components of the treatment program reflected the desire to devise a treatment plan specially tailored to the condition of the patients participating in the study. However, the formulation of specific guidelines on physical therapy programs used as part of fatigue treatment requires more research. In most published studies, the selection of specific physiotherapy techniques is quite varied. Therapies include, among others, active exercises (resisted and unresisted), balance exercises, breathing and relaxation and ergometer training \[[@CR4]--[@CR27]\]. The selection of specific therapies should be based on a careful individual analysis of the potential and limitations of particular patients. This is especially important in a population of patients diagnosed with advanced cancer receiving palliative care. They tend to be reluctant to undertake physical activity giving reasons such as limited fitness and functional capacity \[[@CR43]\]. Moreover, in this population, fatigue is often accompanied by the anorexia-cachexia syndrome. The patient who notes a progressive loss of body mass and suffers from anorexia, whose fatigue increases with each movement, may at first refuse to participate in any treatment proposed by a physiotherapist for fear that his/her exhaustion may increase. Hence, the physiotherapy program should include both the treatment elements that do not require large expenditures of energy on the part of the patients and methods that actively engage them. For this reason, the proposed program included relaxation techniques (myofascial relaxation, breathing stimulation) and more active methods (active exercises, selected PNF techniques).

The rationale for the use of this kind of fatigue treatment programs was evaluated in studies conducted by Fernández-Lao et al. \[[@CR44], [@CR45]\] among patients with breast cancer once they completed their anticancer treatment. The proposed physiotherapy regime included core stability exercises and elements of myofascial release. Results of the study indicate a high effectiveness of the proposed physiotherapy program in relieving fatigue and other symptoms associated with anxiety and depression. Moreover, the treatments improved the patients' muscle strength and their overall fitness. Similar positive therapeutic effects were not observed in the control group.

In devising physiotherapy programs for the treatment of fatigue, it is very important to include simple exercises easy to remember by the patient. The inclusion of such therapy forms is of great importance since they can be used as part of movement activation exercises to be performed by each patient individually.

The results of the present study clearly demonstrate that cancer-related fatigue in patients with advanced cancer constitutes an indication for the inclusion of physiotherapy in their non-pharmacological treatment. However, the issue requires more detailed research involving large groups of advanced cancer patients receiving palliative, hospice and home care, respectively.

The main limitation of the study was the fact that despite the randomization, the process of group assignment itself showed a significant association with gender (*P* = 0.03). It is worth noting, however, that there was no significant correlation between gender and the effect of physiotherapy on the severity of fatigue.

Conclusions {#Sec18}
===========

The proposed physiotherapy program significantly reduces the severity of fatigue in patients diagnosed with advanced cancer receiving palliative care. Additionally, this program improves the general well-being of patients and reduces the severity of their comorbid symptoms, especially pain, drowsiness, loss of appetite and depression. The proposed physiotherapy program was positively rated by patients who completed treatment satisfaction questionnaire. Non-pharmacological treatment of fatigue in advanced cancer patients receiving palliative care should include an appropriate selection of physiotherapy methods.

ANOVA, analysis of variance; BFI, Brief Fatigue Inventory; CI, confidence interval; CRF, cancer-related fatigue; ESAS, Edmonton Symptom Assessment Scale; LSD, least significant difference; MFR, myofascial release; NCCN, National Comprehensive Cancer Network; NRS, Numerical Rating Scale; *P*, borderline level of statistical significance; PNF, proprioceptive neuromuscular facilitation; SD, standard deviation; SS, satisfaction scores

An erratum to this article is available at <https://doi.org/10.1007/s00520-017-3779-4>.
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